American Oncology Network Inc (AONC): Kapitalisasi marang pendapatan

Simbol lan logo merek AON (AONC)

Amid growing demand for private oncology center support and AI-driven digitalization of records, American Oncology Network is facing inflationary pressure on the cost of imported equipment. The current P/S ratio confirms the impact of these costs on share prices, where 0.00 serves as the base parameter value. This chart clearly demonstrates the market reaction to fundamental shifts in the company's operating expenses.

AONC Rasio rega marang pendapatan American Oncology Network Inc (30.03.2024 - 04.08.2024)

Rincian analitis perusahaan American Oncology Network Inc (AONC)

- nilai saham lan prakiraan konsensus rega:
- data kapitalisasi bursa:
Analisis umum perusahaan:AONC American Oncology Network
Barang utama American Oncology Network, Inc.

American Oncology Network (AONC) is scaling its B2B platform for the consolidation of regional US oncology clinics, aiming for dominance in the specialized treatment market. By analyzing the current P/S ratio, an investor assesses market capitalization relative to revenue, which, amid inflation, confirms the business's ability to pass costs onto consumers and determines the real resilience of the share price.

Pesaing American Oncology Network

ONC - Rega marang dodolan|Multiplikator P/S HALO (Halozyme Therapeutics, Inc.)|Revolution Medicines (RVMD) - Rega marang dodolan|ascentage.com - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan CGON (cgoncology.com)|URGN: Multiplikator P/S|Bicara Therapeutics Inc (BCAX) - Multiplikator P/S|Rasio rega marang pendapatan personalis.com|Kapitalisasi marang pendapatan Erasca Corp (ERAS)|Kapitalisasi marang pendapatan DCTH (Delcath)|Koefisien rega marang pendapatan Y-mAbs Therapeutics, Inc.|Multiplikator P/S AURA (Aura Biosciences Inc)|Rasio kapitalisasi pasar marang pendapatan CADL|ARAY: Kapitalisasi marang pendapatan|Koefisien rega marang pendapatan sellaslifesciences.com SLS|ACTU (Actuate Therapeutics, Inc) - Kapitalisasi marang pendapatan|Rasio kapitalisasi marang pendapatan CTOR|Rasio rega marang pendapatan TuHURA Biosciences Inc.|TARA: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Fate Therapeutics (FATE)|Koefisien rega marang pendapatan Aadi Bioscience|Rasio rega marang pendapatan TScan Therapeutics Inc TCRX|CSBR: Rasio kapitalisasi marang pendapatan|XBIT: Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan CVM (cel-sci.com)|OSTX: Multiplikator P/S|Rega marang dodolan Radiopharm Theranostics Ltd (RADX)|ARTV (Artiva) - Multiplikator P/S|Rasio kapitalisasi marang pendapatan ANL (Adlai Nortye)|Rasio rega marang pendapatan Veru Pharma (VERU)|Multiplikator P/S Tempest Tx (TPST)|Rasio rega marang pendapatan xiliotx.com XLO|Enochian BioSciences - Rasio rega marang pendapatan|Mural Oncology - Multiplikator P/S|KAPA - Multiplikator P/S|OnKure Therapeutics Inc (OKUR) - Rasio rega marang pendapatan|Kapitalisasi marang pendapatan CytoMed|Rasio rega marang pendapatan curis.com|Kapitalisasi marang pendapatan Apollomics, Inc. (APLM)|Multiplikator P/S THAR|Advanced Biomed Corp - Rasio kapitalisasi marang pendapatan|Rasio rega marang pendapatan Genprex GNPX|Koefisien rega marang pendapatan Calidi Bio (CLDI)|sunshinebiopharma.com - Multiplikator P/S|Rega marang dodolan xeneticbio.com|salariuspharma.com (SLRX) - Rasio rega marang pendapatan|Purple Biotech Ltd. - Rasio kapitalisasi pasar marang pendapatan|Kapitalisasi marang pendapatan BGNE|Multiplikator P/S Checkpoint Therapeutics Inc.|Multiplikator P/S ELEV|Kapitalisasi marang pendapatan iCAD ICAD|Multiplikator P/S IKNA (Ikena Oncology, Inc.)|Rasio kapitalisasi pasar marang pendapatan NTBL|Viracta Therapeutics, Inc. - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan MOR (MorphoSys Inc)|NAYA (NAYA Biosciences Inc) - Kapitalisasi marang pendapatan|Kapitalisasi marang pendapatan Ascentage Pharma Group Ltd